Article Text


Absence of constitutional H2AX gene mutations in 101 hereditary breast cancer families
  1. A N A Monteiro1,
  2. S Zhang2,
  3. C M Phelan2,
  4. S A Narod2
  1. 1Strang Cancer Prevention Center and Department of Cell and Developmental Biology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
  2. 2Center for Research in Women’s Health, 790 Bay Street, Suite 750A, Toronto M5G1N8, Ontario, Canada
  1. Correspondence to:
 Dr A N A Monteiro, Laboratory of Molecular Oncology, Strang Cancer Research Laboratory, Rockefeller University - Box 231, 1230 York Avenue, New York, NY 10021, USA; 

Statistics from

Several genes involved in the DNA damage response and in maintaining genomic stability have emerged as breast cancer susceptibility genes. These include BRCA1 and BRCA2, as well as other genes with smaller contributions to breast cancer aetiology, such as TP53, CHEK2, and ATM. Germline mutations in BRCA1 and BRCA2 increase sensitivity to DNA damage and decrease cellular capacity to repair double strand DNA breaks through homologous recombination.1–3 Interestingly, DNA damage induces activation of ATM (ataxia-telangiectasia mutated), which performs a central role in relaying signals that orchestrate DNA repair.4 People with heterozygous nonsense mutations in ATM appear to display increased susceptibility to breast cancer.5–7 Besides rapidly phosphorylating BRCA1,8 activated ATM also phosphorylates p53 and CHEK2 (CHK2, hCDS1), which have been implicated in breast cancer predisposition. Germline mutations in TP53 or CHEK2 cause Li-Fraumeni syndrome, a multiple cancer phenotype syndrome, which features early onset breast cancer.9,10 Recently, it was found that germline mutations in CHEK2 also increase the relative risk for breast cancer outside the Li-Fraumeni syndrome.11,12 Given the emerging relationship of impaired DNA damage response and breast cancer susceptibility, we hypothesised that other genes in this pathway might be candidate cancer susceptibility genes.

Histone H2AX (H2AFX, OMIM 601772) is such a candidate gene. H2AX is a minor variant of the highly conserved histone H2A that is part of the histone octamer in the core of the nucleosome.13 It differs from H2A by having a longer carboxy-terminal tail that contains an SQE motif, a consensus site for phosphorylation by PI3K related kinases such as ATM, ATR, and DNA-PK. Following DNA damage, ATM phosphorylates H2AX at serine 139 (part of the SQE motif)14 and phosphorylated H2AX (γ-H2AX) seems to localise specifically at sites of damage.15,16 More importantly, several proteins involved in DNA repair including BRCA1, BRCA2, Rad51, and Mre11 are recruited to sites of γ-H2AX.16 Two other independent lines of evidence derived from model organisms support the notion that H2AX plays an important role in the DNA damage response and in chromosomal stability. Phosphorylation of S129 of Saccharomyces cerevisiae H2A (homologous to S139 in human H2AX) is necessary for efficient processing of DNA repair and is proposed to cause alteration of chromatin structure that facilitates repair.17 Mice lacking H2AX are sensitive to radiation, are growth retarded, and their cells display high levels of ionising radiation induced chromosomal instability.18,19 Thus, although the exact function of H2AX is still unknown, it is clear that it plays a role in the DNA damage response.

To establish if germline H2AX mutations are present in breast cancer families, DNA samples were obtained from 101 unrelated breast cancer patients.


Each of these patients was from a family with three or more cases of breast cancer. These families were selected because they have previously been tested for the presence of germline mutations in BRCA1 and BRCA2 using the protein truncation test (PTT) and no mutations were found. There were, on average, 4.2 cases of breast cancer per family (range 3 to 11) with an average of 3.0 cases of breast cancer in first degree relatives per family (range 2 to 9). Seventeen of the families also contained cases of ovarian cancer. For each family, a single patient affected with breast cancer was studied, with a mean age of diagnosis of 47 years (range 24 to 72 years).

Key points

  • Several genes whose products participate in the cellular response to DNA damage have emerged as breast cancer susceptibility genes. These genes include BRCA1, BRCA2, ATM, CHEK2, and TP53 and germline mutations in these genes increase the predisposition to breast cancer.

  • We hypothesised that other genes in the DNA damage response pathway might also be breast cancer susceptibility genes. The gene for histone H2AX is such a candidate. Its product is an early substrate of ATM kinase activity following DNA damage. Phosphorylated H2AX (γ-H2AX) colocalises with DNA breaks, and other proteins involved in DNA repair such as BRCA1, Rad51, and Mre11 are recruited to γ-H2AX sites.

  • We screened subjects from 101 families with hereditary breast cancer by direct sequencing of H2AX coding sequence. We did not detect any mutations or sequence variants in this sample, suggesting that it is unlikely that germline mutations in H2AX play a major role in hereditary breast cancer.

The H2AX gene contains a single exon with 432 nucleotides. The coding sequence of the H2AX gene was evaluated by direct sequencing of a 561 bp fragment amplified using the following primers: F5′-CGTCTGTTCTAGTGTTTGAGC-3′ and R5′-TGAGGGCGGTGGTGGCCCTTAA-3′. No mutations or sequence variants were found in the 101 patients.


Our results suggest that germline H2AX mutations are unlikely to be common in families with familial breast cancer. Furthermore, the absence of polymorphic variation in this gene precludes the possibility that missense variants within the coding region of H2AX are associated with breast cancer risk in the population as a whole. It is, of course, possible that rare disease causing mutations in H2AX exist, and these might be uncovered in a larger study.


This work was supported by the Canadian Genetic Diseases Network, the Canadian Breast Cancer Research Foundation (Ontario chapter), and the Canadian Breast Cancer Research Initiative. CMP is funded by US Army grant DAMD17-00-1-0478. ANAM is funded by the Julia Murtha Fund, US Army award DAMD17-99-1-9389 and NIH CA92309.


View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.